Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.59 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.59 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35210320 | 1.00 | EGFR (0.59) | EGFRERBB3DUS2KDRFGFR1 | |
| SCHEMBL19089628 | 0.93 | EGFR (0.55) | EGFRERBB3DUS2KDRFGFR1 | |
| SCHEMBL35210345 | 0.93 | EGFR (0.55) | EGFRERBB3DUS2KDRFGFR1 | |
| SCHEMBL19089546 | 0.91 | EGFR (0.62) | EGFRERBB3DUS2KDRERBB2 | |
| SCHEMBL20548919 | 0.88 | EGFR (0.58) | EGFRERBB3DUS2 | |
| SCHEMBL35210335 | 0.88 | EGFR (0.58) | EGFRERBB3DUS2 | |
| SCHEMBL35210333 | 0.86 | EGFR (0.56) | EGFRERBB3DUS2KDRERBB2 | |
| SCHEMBL19089512 | 0.86 | EGFR (0.56) | EGFRERBB3DUS2KDRERBB2 | |
| SCHEMBL20656043 | 0.86 | EGFR (0.52) | EGFRERBB3DUS2KDRFGFR1 | |
| SCHEMBL20548833 | 0.86 | EGFR (0.58) | EGFRERBB3DUS2KDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398939-B1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2026-05-06 | — | — | EP | claimed |
| CN-106928150-B | Acrylamide aniline derivative and pharmaceutical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2020-07-31 | — | — | CN | claimed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | claimed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | claimed |
| EP-3398939-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2018-11-07 | — | — | EP | claimed |
| EP-3398939-B1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3398939-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017114500-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | 恩瑞生物医药科技（上海）有限公司 | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ERBB3 8/4885DUS2 2790/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ERBB3 8/4885DUS2 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.